Released Aug 14, 2025, after the close
10-Q filed Aug 14, 2025, 45 days after period end · 0001410578-25-001809
Q2 2025 · 10-Q
Revenue$1.98M$1.98M +1.4% vs Q2 2024−15.4% vs Q1 2025
Net Income-$15.70M-$15.70M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.52-$0.52 N/M vs Q2 2024N/M vs Q1 2025
Gross Profit$1,618,000+13.9%
Operating Income-$13,806,000N/M
Operating Cash Flowderived-$13,744,000N/M
Margins · derived
Gross margin81.7%+8.9 pt vs Q2 2024
Operating margin-696.9%−295.4 pt vs Q2 2024
Net margin-792.3%−438.0 pt vs Q2 2024
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 |
|---|---|---|
| Revenue | $1.98M | $1.95M |
| Net Income | -$15.70M | -$6.92M |
| EPS Diluted | -$0.52 | $0.28 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR